TD Asset Management Inc Purchases 371,856 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Key Points

• TD Asset Management Inc increased its stake in Amphastar Pharmaceuticals by 20.2% in the first quarter, owning 4.66% of the company, valued at approximately $64.13 million.
• Several analysts have recently adjusted their price targets for Amphastar Pharmaceuticals, with Wells Fargo lowering its target from $40 to $35 and JPMorgan reducing its target from $45 to $30, indicating a cautious outlook.
• Amphastar Pharmaceuticals currently has a market capitalization of $1.05 billion, a price-to-earnings ratio of 8.11, and a recent trading range of $20.43 to $53.96 over the past year.

TD Asset Management Inc lifted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 20.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 2,212,142 shares of the company's stock after acquiring an additional 371,856 shares during the period. TD Asset Management Inc owned approximately 4.66% of Amphastar Pharmaceuticals worth $64,130,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Signaturefd LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after acquiring an additional 520 shares during the last quarter. IFP Advisors Inc bought a new stake in shares of Amphastar Pharmaceuticals during the 1st quarter worth $34,000. GF Fund Management CO. LTD. bought a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth $38,000. GAMMA Investing LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after acquiring an additional 424 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after acquiring an additional 348 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Trading Down 0.6%

Shares of Amphastar Pharmaceuticals stock traded down $0.13 during trading on Thursday, reaching $21.21. The company's stock had a trading volume of 164,476 shares, compared to its average volume of 560,875. Amphastar Pharmaceuticals, Inc. has a 52-week low of $20.43 and a 52-week high of $53.96. The company has a market cap of $999.68 million, a price-to-earnings ratio of 7.68 and a beta of 0.72. The firm's 50-day moving average is $23.84 and its two-hundred day moving average is $27.00. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on AMPH shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Finally, Wells Fargo & Company cut their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.